Characterisation of the pharmacokinetic profile of L-DOPA in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of L-3,4-dihydroxyphenylalanine (L-DOPA) in the common marmoset (Callithrix jacchus). Background: The common marmoset has been used to model…Asymmetry of striatal dopaminergic function in essential tremor is associated with kinetic tremor asymmetry
Objective: To investigate possible dopaminergic pathophysiology of essential tremor (ET) by focusing on tremor asymmetry. Background: Essential tremor (ET) is considered a non-dopaminergic movement disorder.…Real-World Utilization of Istradefylline Among Patients with Parkinson’s Disease
Objective: This study examined real-world utilization of istradefylline and other PD-related medications before and after istradefylline initiation. Background: Istradefylline is indicated as adjunctive therapy to…Anxiety in Parkinson’s disease is associated with changes in brain structural connectivity
Objective: The aim of this study was to identify White Matter (WM) changes by comparing Parkinson's disease (PD) patients with and without anxiety, using diffusion-tensor…Genetic and psychiatric risk factors for impulse control disorders in de novo Parkinson’s disease
Objective: To assess the interplay of polygenic dopamine risk scores and psychiatric symptoms in the development of impulse control disorders (ICDs) in de novo patients…Quantitative analysis of speech diadochokinetic rate in hereditary spastic paraplegia SPG3A
Objective: To analyze the dysarthria and speech diadochokinetic rate in a patient with hereditary spastic paraplegia (SPG3A). Background: Hereditary spastic paraplegias (HSP) are about 80…Non-motor symptoms of Parkinson’s disease: an analysis of gender and age-related differences in a large online cohort
Objective: This study analyzed non-motor symptoms in newly diagnosed Parkinson’s disease (PD) patients and controls in a large online cohort, comparing four groups based on…Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson’s disease (PD): the LIXIPARK trial (NCT03439943)
Objective: To evaluate the “disease-modifying” effect of lixisenatide as adjunct to antiparkinsonian medications in patients with early PD. Background: Lixisenatide, a glucagon-like peptide 1 receptor…Stability of basal ganglia beta band power distribution during continuous deep brain stimulation in Parkinson’s disease: analysis of sub-cohort from the ADAPT-PD trial
Objective: To assess the stability of the daily distribution of peak subthalamic nucleus (STN) and globus pallidus internus (GPi) beta band power during continuous deep…Evaluation of Cognitive Assessment Tools in Parkinson’s Disease
Objective: To evaluate a variety of cognitive assessment scales in a longitudinal Parkinson’s disease (PD) cohort. Background: Cognitive impairment is one of the most common and…
- « Previous Page
- 1
- …
- 162
- 163
- 164
- 165
- 166
- …
- 186
- Next Page »